Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies
This study has been terminated.
Study NCT00050687   Information provided by Titan Pharmaceuticals
First Received: December 17, 2002   Last Updated: August 19, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Prostatic Neoplasms
Multiple Myeloma
Bladder Neoplasms
Lymphoma
Additional conditions recognized in this trial
Neoplasms
Neoplasms, Plasma Cell
Urinary Bladder Neoplasms
More general conditions related to this trial
Blood Protein Disorders
Cardiovascular Diseases
Genital Diseases, Male
Genital Neoplasms, Male
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Neoplasms by Site
Paraproteinemias
Prostatic Diseases
Urinary Bladder Diseases
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Vascular Diseases
Interventions listed in this trial
Gallium maltolate
Sponsors listed in this trial
Titan Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services